{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:24:02Z","timestamp":1787743442377,"version":"build-2784847793"},"reference-count":215,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","award":["NIHR203316"],"award-info":[{"award-number":["NIHR203316"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Aging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Psychotic disorders, including schizophrenia and affective psychosis, affect ~3% of the population and typically emerge in early adulthood. Cardiometabolic disease accounts for much of the 20-year life-expectancy gap in psychosis. Evidence indicates potentially causal processes, often seen in aging, act within and beyond the brain, and before the onset of treatment; these include inflammation, metabolic and mitochondrial dysfunction. Here we synthesize evidence and propose a framework that proposes psychosis as a multisystem disorder of accelerated aging, and outline implications for aging-targeted interventions.<\/jats:p>","DOI":"10.1038\/s41514-026-00409-2","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:17:53Z","timestamp":1780071473000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Psychosis as a multisystem disorder of aberrant aging"],"prefix":"10.1038","volume":"12","author":[{"given":"Rachel","family":"Upthegrove","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalie C. M.","family":"Couch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"de Marvao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin I.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Corsi-Zuelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lahiru","family":"Handunnetthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas M.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Koutsouleris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paris A.","family":"Lalousis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Pillinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Freyberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"409_CR1","doi-asserted-by":"crossref","unstructured":"Jaaro-Peled, H. & Sawa, A. Neurodevelopmental Factors in Schizophrenia. Psychiatr. Clin. N. Am. 43, 263\u2013274 (2020).","DOI":"10.1016\/j.psc.2020.02.010"},{"key":"409_CR2","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1001\/jamapsychiatry.2015.1546","volume":"72","author":"AR Ribe","year":"2015","unstructured":"Ribe, A. R. et al. Long-term risk of dementia in persons with schizophrenia: a Danish population-based cohort study. JAMA Psychiatry 72, 1095\u20131101 (2015).","journal-title":"JAMA Psychiatry"},{"key":"409_CR3","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1001\/jamapsychiatry.2018.2726","volume":"75","author":"BG Druss","year":"2018","unstructured":"Druss, B. G. Can better cardiovascular care close the mortality gap for people with schizophrenia? JAMA Psychiatry 75, 1269\u20131270 (2018).","journal-title":"JAMA Psychiatry"},{"key":"409_CR4","doi-asserted-by":"crossref","unstructured":"Pillinger, T. et al. Cardiac structure and function in patients with schizophrenia taking antipsychotic drugs: an MRI study. Transl. Psychiatry 9, 163 (2019).","DOI":"10.1038\/s41398-019-0502-x"},{"key":"409_CR5","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1001\/jamapsychiatry.2020.4180","volume":"78","author":"BI Perry","year":"2021","unstructured":"Perry, B. I. et al. Longitudinal trends in childhood insulin levels and body mass index and associations with risks of psychosis and depression in young adults. JAMA Psychiatry 78, 416\u2013425 (2021).","journal-title":"JAMA Psychiatry"},{"key":"409_CR6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/schbul\/sby040","volume":"45","author":"BI Perry","year":"2019","unstructured":"Perry, B. I. et al. Dysglycaemia, inflammation and psychosis: findings from the UK ALSPAC Birth Cohort. Schizophr. Bull. 45, 330\u2013338 (2019).","journal-title":"Schizophr. Bull."},{"key":"409_CR7","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1017\/S0033291721005213","volume":"53","author":"T Pillinger","year":"2023","unstructured":"Pillinger, T., McCutcheon, R. A. & Howes, O. D. Variability of glucose, insulin, and lipid disturbances in first-episode psychosis: a meta-analysis. Psychol. Med. 53, 3150\u20133156 (2023).","journal-title":"Psychol. Med."},{"key":"409_CR8","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/schbul\/sby160","volume":"45","author":"T Pillinger","year":"2019","unstructured":"Pillinger, T. et al. A meta-analysis of immune parameters, variability, and assessment of modal distribution in psychosis and test of the immune subgroup hypothesis. Schizophr. Bull. 45, 1120\u20131133 (2019).","journal-title":"Schizophr. Bull."},{"key":"409_CR9","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1001\/jamapsychiatry.2024.2193","volume":"81","author":"ER Palmer","year":"2024","unstructured":"Palmer, E. R. et al. Trajectories of inflammation in youth and risk of mental and cardiometabolic disorders in adulthood. JAMA Psychiatry 81, 1130\u20131137 (2024).","journal-title":"JAMA Psychiatry"},{"key":"409_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.schres.2014.03.005","volume":"155","author":"R Upthegrove","year":"2014","unstructured":"Upthegrove, R., Manzanares-Teson, N. & Barnes, N. M. Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr. Res. 155, 101\u2013108 (2014).","journal-title":"Schizophr. Res."},{"key":"409_CR11","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S2215-0366(16)30262-0","volume":"3","author":"BI Perry","year":"2016","unstructured":"Perry, B. I., McIntosh, G., Weich, S., Singh, S. & Rees, K. The association between first-episode psychosis and abnormal glycaemic control: systematic review and meta-analysis. Lancet Psychiatry 3, 1049\u20131058 (2016).","journal-title":"Lancet Psychiatry"},{"key":"409_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1192\/bjp.bp.117.200907","volume":"211","author":"T Pillinger","year":"2017","unstructured":"Pillinger, T., Beck, K., Stubbs, B. & Howes, O. D. Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis. Br. J. Psychiatry 211, 339\u2013349 (2017).","journal-title":"Br. J. Psychiatry"},{"key":"409_CR13","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41380-018-0058-9","volume":"24","author":"T Pillinger","year":"2019","unstructured":"Pillinger, T., D\u2019Ambrosio, E., McCutcheon, R. & Howes, O. D. Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models. Mol. Psychiatry 24, 776\u2013794 (2019).","journal-title":"Mol. Psychiatry"},{"key":"409_CR14","doi-asserted-by":"publisher","unstructured":"Andreazza, A. C. et al. Brain and body energy metabolism and potential for treatment of psychiatric disorders. Nat. Ment. Health 1\u20139. https:\/\/doi.org\/10.1038\/s44220-025-00422-6 (2025).","DOI":"10.1038\/s44220-025-00422-6"},{"key":"409_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1192\/bjp.bp.117.202606","volume":"211","author":"JF Hayes","year":"2017","unstructured":"Hayes, J. F., Marston, L., Walters, K., King, M. B. & Osborn, D. P. J. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000\u20132014. Br. J. Psychiatry 211, 175\u2013181 (2017).","journal-title":"Br. J. Psychiatry"},{"key":"409_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.schres.2017.09.005","volume":"196","author":"EE Lee","year":"2018","unstructured":"Lee, E. E. et al. A widening longevity gap between people with schizophrenia and general population: a literature review and call for action. Schizophr. Res. 196, 9\u201313 (2018).","journal-title":"Schizophr. Res."},{"key":"409_CR17","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/schbul\/sbu138","volume":"41","author":"U Reininghaus","year":"2015","unstructured":"Reininghaus, U. et al. Mortality in schizophrenia and other psychoses: a 10-year follow-up of the \u04d4SOP first-episode cohort. Schizophr. Bull. 41, 664\u2013673 (2015).","journal-title":"Schizophr. Bull."},{"key":"409_CR18","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/S0140-6736(19)32316-5","volume":"394","author":"O Plana-Ripoll","year":"2019","unstructured":"Plana-Ripoll, O. et al. A comprehensive analysis of mortality-related health metrics associated with mental disorders: a nationwide, register-based cohort study. Lancet 394, 1827\u20131835 (2019).","journal-title":"Lancet"},{"key":"409_CR19","doi-asserted-by":"crossref","unstructured":"Corsi-Zuelli, F. et al. Depressive and negative symptoms in the early and established stages of schizophrenia: integrating structural brain alterations, cognitive performance, and plasma interleukin 6 levels. Biol. Psychiatry Glob. Open Sci. 5, 100429 (2024).","DOI":"10.1016\/j.bpsgos.2024.100429"},{"key":"409_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.bbi.2023.06.023","volume":"113","author":"P Alexandros Lalousis","year":"2023","unstructured":"Alexandros Lalousis, P. et al. Inflammatory subgroups of schizophrenia and their association with brain structure: a semi-supervised machine learning examination of heterogeneity. Brain Behav. Immun. 113, 166\u2013175 (2023).","journal-title":"Brain Behav. Immun."},{"key":"409_CR21","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s41569-023-00881-3","volume":"20","author":"M Abdellatif","year":"2023","unstructured":"Abdellatif, M., Rainer, P. P., Sedej, S. & Kroemer, G. Hallmarks of cardiovascular ageing. Nat. Rev. Cardiol. 20, 754\u2013777 (2023).","journal-title":"Nat. Rev. Cardiol."},{"key":"409_CR22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S2215-0366(22)00403-5","volume":"10","author":"T Pillinger","year":"2023","unstructured":"Pillinger, T. et al. Effect of polygenic risk for schizophrenia on cardiac structure and function: a UK Biobank observational study. Lancet Psychiatry 10, 98\u2013107 (2023).","journal-title":"Lancet Psychiatry"},{"key":"409_CR23","doi-asserted-by":"crossref","unstructured":"Gensous, N. et al. A targeted epigenetic clock for the prediction of biological age. Cells 11, 4044 (2022).","DOI":"10.3390\/cells11244044"},{"key":"409_CR24","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1186\/s13041-021-00810-w","volume":"14","author":"LC Steg","year":"2021","unstructured":"Steg, L. C. et al. Novel epigenetic clock for fetal brain development predicts prenatal age for cellular stem cell models and derived neurons. Mol. Brain 14, 3489\u20133501 (2021).","journal-title":"Mol. Brain"},{"key":"409_CR25","doi-asserted-by":"crossref","unstructured":"Argentieri, M. A. et al. Proteomic aging clock predicts mortality and risk of common age-related diseases in diverse populations. Nat. Med. 30, 2450\u20132460 (2024).","DOI":"10.1038\/s41591-024-03164-7"},{"key":"409_CR26","doi-asserted-by":"crossref","unstructured":"Smith, S. M. et al. Brain aging comprises many modes of structural and functional change with distinct genetic and biophysical associations. eLife 9, e52677 (2020).","DOI":"10.7554\/eLife.52677"},{"key":"409_CR27","doi-asserted-by":"crossref","unstructured":"Vita, A., De Peri, L., Deste, G. & Sacchetti, E. Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. Transl. Psychiatry 2, e190 (2012).","DOI":"10.1038\/tp.2012.116"},{"key":"409_CR28","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.biopsych.2011.05.017","volume":"70","author":"NC Andreasen","year":"2011","unstructured":"Andreasen, N. C. et al. Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia. Biol. Psychiatry 70, 672\u2013679 (2011).","journal-title":"Biol. Psychiatry"},{"key":"409_CR29","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/archpsyc.58.2.148","volume":"58","author":"DH Mathalon","year":"2001","unstructured":"Mathalon, D. H., Sullivan, E. V., Lim, K. O. & Pfefferbaum, A. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch. Gen. Psychiatry 58, 148\u2013157 (2001).","journal-title":"Arch. Gen. Psychiatry"},{"key":"409_CR30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/acps.13371","volume":"145","author":"PL Ballester","year":"2022","unstructured":"Ballester, P. L. et al. Brain age in mood and psychotic disorders: a systematic review and meta-analysis. Acta Psychiatr. Scand. 145, 42\u201355 (2022).","journal-title":"Acta Psychiatr. Scand."},{"key":"409_CR31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jpsychires.2022.11.011","volume":"157","author":"KV Blake","year":"2023","unstructured":"Blake, K. V. et al. Advanced brain ageing in adult psychopathology: a systematic review and meta-analysis of structural MRI studies. J. Psychiatr. Res. 157, 180\u2013191 (2023).","journal-title":"J. Psychiatr. Res."},{"key":"409_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bbi.2023.09.017","volume":"115","author":"AJ Murray","year":"2024","unstructured":"Murray, A. J. et al. Measurement of brain glutathione with magnetic Resonance spectroscopy in Schizophrenia-Spectrum disorders\u2014a systematic review and Meta-Analysis. Brain Behav. Immun. 115, 3\u201312 (2024).","journal-title":"Brain Behav. Immun."},{"key":"409_CR33","doi-asserted-by":"publisher","first-page":"703452","DOI":"10.3389\/fpsyt.2021.703452","volume":"12","author":"AJ Murray","year":"2021","unstructured":"Murray, A. J., Rogers, J. C., Katshu, M. Z. U. H., Liddle, P. F. & Upthegrove, R. Oxidative stress and the pathophysiology and symptom profile of schizophrenia spectrum disorders. Front. Psychiatry 12, 703452 (2021).","journal-title":"Front. Psychiatry"},{"key":"409_CR34","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/s41380-022-01897-w","volume":"28","author":"C Constantinides","year":"2023","unstructured":"Constantinides, C. et al. Brain ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA Schizophrenia consortium. Mol. Psychiatry 28, 1201\u20131209 (2023).","journal-title":"Mol. Psychiatry"},{"key":"409_CR35","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/schbul\/sbae074","volume":"50","author":"JPY Hua","year":"2024","unstructured":"Hua, J. P. Y. et al. Brain age gap in early illness schizophrenia and the clinical high-risk syndrome: associations with experiential negative symptoms and conversion to psychosis. Schizophr. Bull. 50, 1159\u20131170 (2024).","journal-title":"Schizophr. Bull."},{"key":"409_CR36","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.neuroimage.2007.10.029","volume":"39","author":"N Koutsouleris","year":"2008","unstructured":"Koutsouleris, N. et al. Structural correlates of psychopathological symptom dimensions in schizophrenia: a voxel-based morphometric study. Neuroimage 39, 1600\u20131612 (2008).","journal-title":"Neuroimage"},{"key":"409_CR37","doi-asserted-by":"crossref","unstructured":"Smith, S. M., Miller, K. L. & Nichols, T. E. Characterising ongoing brain aging and baseline eff ects from cross-sectional data. Imaging Neuroscience. 3 IMAG.a.39 (2025).","DOI":"10.1162\/IMAG.a.39"},{"key":"409_CR38","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/schbul\/sbab149","volume":"48","author":"X Chen","year":"2022","unstructured":"Chen, X. et al. White matter metabolite relaxation and diffusion abnormalities in first-episode psychosis: a longitudinal study. Schizophr. Bull. 48, 712\u2013720 (2022).","journal-title":"Schizophr. Bull."},{"key":"409_CR39","doi-asserted-by":"publisher","first-page":"16621","DOI":"10.1073\/pnas.0706778104","volume":"104","author":"R Gysin","year":"2007","unstructured":"Gysin, R. et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc. Natl. Acad. Sci. USA. 104, 16621\u201316626 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"409_CR40","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41580-019-0101-y","volume":"20","author":"MS Hipp","year":"2019","unstructured":"Hipp, M. S., Kasturi, P. & Hartl, F. U. The proteostasis network and its decline in ageing. Nat. Rev. Mol. Cell Biol. 20, 421\u2013435 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"409_CR41","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cell.2022.11.001","volume":"186","author":"C L\u00f3pez-Ot\u00edn","year":"2023","unstructured":"L\u00f3pez-Ot\u00edn, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. Hallmarks of aging: an expanding universe. Cell 186, 243\u2013278 (2023).","journal-title":"Cell"},{"key":"409_CR42","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s43587-021-00082-y","volume":"1","author":"N Sayed","year":"2021","unstructured":"Sayed, N. et al. An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging. Nat. Aging 1, 598\u2013615 (2021).","journal-title":"Nat. Aging"},{"key":"409_CR43","doi-asserted-by":"crossref","unstructured":"Oh, H. S.-H. et al. Plasma proteomics links brain and immune system aging with healthspan and longevity. Nat. Med. 31, 2703--2711 (2025).","DOI":"10.1038\/s41591-025-03798-1"},{"key":"409_CR44","doi-asserted-by":"crossref","unstructured":"Kersh, A. E. et al. CXCL9, CXCL10, and CCL19 synergistically recruit T lymphocytes to skin in lichen planus. JCI Insight 9, e179899 (2024).","DOI":"10.1172\/jci.insight.179899"},{"key":"409_CR45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fncel.2015.00073","volume":"9","author":"T Gorkiewicz","year":"2015","unstructured":"Gorkiewicz, T., Balcerzyk, M., Kaczmarek, L. & Knapska, E. Matrix metalloproteinase 9 (MMP-9) is indispensable for long term potentiation in the central and basal but not in the lateral nucleus of the amygdala. Front. Cell. Neurosci. 9, 73 (2015).","journal-title":"Front. Cell. Neurosci."},{"key":"409_CR46","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1523\/JNEUROSCI.4359-05.2006","volume":"26","author":"V Nagy","year":"2006","unstructured":"Nagy, V. et al. Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J. Neurosci. 26, 1923\u20131934 (2006).","journal-title":"J. Neurosci."},{"key":"409_CR47","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3389\/fncel.2015.00280","volume":"9","author":"SM Reinhard","year":"2015","unstructured":"Reinhard, S. M., Razak, K. & Ethell, I. M. A delicate balance: role of MMP-9 in brain development and pathophysiology of neurodevelopmental disorders. Front. Cell. Neurosci. 9, 280 (2015).","journal-title":"Front. Cell. Neurosci."},{"key":"409_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41537-024-00541-6","volume":"10","author":"T Guo","year":"2024","unstructured":"Guo, T. et al. Increased GDF-15 in chronic male patients with schizophrenia: correlation with body mass index and cognitive impairment. Schizophrenia 10, 1\u20138 (2024).","journal-title":"Schizophrenia"},{"key":"409_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-07503-2","volume":"7","author":"P Kumar","year":"2017","unstructured":"Kumar, P. et al. Plasma GDF15 level is elevated in psychosis and inversely correlated with severity. Sci. Rep. 7, 1\u20139 (2017).","journal-title":"Sci. Rep."},{"key":"409_CR50","doi-asserted-by":"crossref","unstructured":"Li, X. et al. Inflammation and aging: signaling pathways and intervention therapies. Signal Transduct. Target. Ther. 8, 239 (2023).","DOI":"10.1038\/s41392-023-01502-8"},{"key":"409_CR51","doi-asserted-by":"publisher","unstructured":"Chui, M. K. K. et al. Associations of systemic inflammation and senescent cell biomarkers with clinical outcomes in older adults with schizophrenia. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2024.03.06.24303857 (2024).","DOI":"10.1101\/2024.03.06.24303857"},{"key":"409_CR52","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41582-019-0265-2","volume":"15","author":"I Fyfe","year":"2019","unstructured":"Fyfe, I. Neurofilament light chain\u2014new potential for prediction and prognosis. Nat. Rev. Neurol. 15, 557 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"409_CR53","doi-asserted-by":"publisher","first-page":"RP89854","DOI":"10.7554\/eLife.89854","volume":"12","author":"A Koumoundourou","year":"2024","unstructured":"Koumoundourou, A. et al. Regulation of hippocampal mossy fiber-CA3 synapse function by a Bcl11b\/C1ql2\/Nrxn3(25b+) pathway. Elife 12, RP89854 (2024).","journal-title":"Elife"},{"key":"409_CR54","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.bbi.2024.01.219","volume":"117","author":"M Koskuvi","year":"2024","unstructured":"Koskuvi, M. et al. Lower complement C1q levels in first-episode psychosis and in schizophrenia. Brain Behav. Immun. 117, 313\u2013319 (2024).","journal-title":"Brain Behav. Immun."},{"key":"409_CR55","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jpsychires.2023.03.027","volume":"161","author":"MF Ceylan","year":"2023","unstructured":"Ceylan, M. F. et al. Changes in neurofilament light chain protein (NEFL) in children and adolescents with Schizophrenia and Bipolar Disorder: early period neurodegeneration. J. Psychiatr. Res. 161, 342\u2013347 (2023).","journal-title":"J. Psychiatr. Res."},{"key":"409_CR56","doi-asserted-by":"crossref","unstructured":"Seitz-Holland, J. et al. Matrix metalloproteinase 9 (MMP-9) activity, hippocampal extracellular free water, and cognitive deficits are associated with each other in early phase psychosis. Neuropsychopharmacology 49, 1140\u20131150 (2024).","DOI":"10.1038\/s41386-024-01814-5"},{"key":"409_CR57","doi-asserted-by":"crossref","unstructured":"Libert, S., Chekholko, A. & Kenyon, C. A mathematical model that predicts human biological age from physiological traits identifies environmental and genetic factors that influence aging. eLife 13, RP92092 (2025).","DOI":"10.7554\/eLife.92092.3"},{"key":"409_CR58","doi-asserted-by":"publisher","unstructured":"Neuhaus, L. et al. NF-\u03baB pathway gene expression is elevated in the midbrain of people with high-inflammation schizophrenia. Brain Behav. Immun. 106562. https:\/\/doi.org\/10.1016\/j.bbi.2026.106562 (2026).","DOI":"10.1016\/j.bbi.2026.106562"},{"key":"409_CR59","doi-asserted-by":"crossref","unstructured":"Luo, X., Dong, J. & Li, T. Comparative cytokine signatures and cognitive deficits in early-onset schizophrenia and adolescent major depression: Toward refined diagnostic classification frameworks. J. Affect. Disord. 389, 119667 (2025).","DOI":"10.1016\/j.jad.2025.119667"},{"key":"409_CR60","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1001\/jamapsychiatry.2022.0407","volume":"79","author":"JA Williams","year":"2022","unstructured":"Williams, J. A. et al. Inflammation and brain structure in schizophrenia and other neuropsychiatric disorders: a Mendelian randomization study. JAMA Psychiatry 79, 498\u2013507 (2022).","journal-title":"JAMA Psychiatry"},{"key":"409_CR61","unstructured":"Guccione, C. et al. Early signs of schizophrenia and autonomic nervous system dysregulation: a literature review. Clin. Neuropsychiatry 16, 86\u201397 2019)."},{"key":"409_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-40566-6","volume":"14","author":"M Shah","year":"2023","unstructured":"Shah, M. et al. Environmental and genetic predictors of human cardiovascular ageing. Nat. Commun. 14, 1\u201315 (2023).","journal-title":"Nat. Commun."},{"key":"409_CR63","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1192\/bjp.2019.268","volume":"217","author":"EF Osimo","year":"2020","unstructured":"Osimo, E. F. et al. Cardiac structure and function in schizophrenia: cardiac magnetic resonance imaging study. Br. J. Psychiatry 217, 450\u2013457 (2020).","journal-title":"Br. J. Psychiatry"},{"key":"409_CR64","doi-asserted-by":"publisher","first-page":"1137892","DOI":"10.3389\/fcvm.2023.1137892","volume":"10","author":"YS Baek","year":"2023","unstructured":"Baek, Y. S. et al. Artificial intelligence-estimated biological heart age using a 12-lead electrocardiogram predicts mortality and cardiovascular outcomes. Front. Cardiovasc. Med. 10, 1137892 (2023).","journal-title":"Front. Cardiovasc. Med."},{"key":"409_CR65","doi-asserted-by":"crossref","unstructured":"Perry, B. I. et al. Evidence for shared genetic aetiology between schizophrenia, cardiometabolic, and inflammation-related traits: genetic correlation and colocalization analyses. Schizophr. Bull. Open 3, sgac001 (2022).","DOI":"10.1093\/schizbullopen\/sgac001"},{"key":"409_CR66","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1126\/sciadv.adp3743","volume":"10","author":"J Mutz","year":"2024","unstructured":"Mutz, J., Iniesta, R. & Lewis, C. M. Metabolomic age (MileAge) predicts health and life span: a comparison of multiple machine learning algorithms. Sci. Adv. 10, 3743 (2024).","journal-title":"Sci. Adv."},{"key":"409_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-52310-9","volume":"15","author":"S Zhang","year":"2024","unstructured":"Zhang, S. et al. A metabolomic profile of biological aging in 250,341 individuals from the UK Biobank. Nat. Commun. 15, 1\u201319 (2024).","journal-title":"Nat. Commun."},{"key":"409_CR68","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/gerona\/glae280","volume":"80","author":"TO Faquih","year":"2025","unstructured":"Faquih, T. O. et al. Robust metabolomic age prediction based on a wide selection of metabolites. J. Gerontol. Ser. A 80, 280 (2025).","journal-title":"J. Gerontol. Ser. A"},{"key":"409_CR69","doi-asserted-by":"publisher","unstructured":"Teasdale, S. B. et al. Metabolic syndrome risk prediction in an Australian sample with first-episode psychosis using the psychosis metabolic risk calculator: a validation study. Australas. Psychiatry https:\/\/doi.org\/10.1177\/10398562241269171\/SUPPL_FILE\/SJ-PDF-1-APY-10.1177_10398562241269171.PDF (2024).","DOI":"10.1177\/10398562241269171\/SUPPL_FILE\/SJ-PDF-1-APY-10.1177_10398562241269171.PDF"},{"key":"409_CR70","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/acps.13752","volume":"151","author":"J Kein\u00e4nen","year":"2025","unstructured":"Kein\u00e4nen, J. et al. Psychosis metabolic risk calculator (PsyMetRiC) in early psychosis: external validation study in Finland. Acta Psychiatr. Scand. 151, 56\u201368 (2025).","journal-title":"Acta Psychiatr. Scand."},{"key":"409_CR71","doi-asserted-by":"crossref","unstructured":"Tse, W. et al. Assessing the generalisability of the psychosis metabolic risk calculator (PsyMetRiC) for young people with first-episode psychosis with validation in a Hong Kong Chinese Han population: a 4-year follow-up study. Lancet Reg. Health West. Pac. 47, 101089 (2024).","DOI":"10.1016\/j.lanwpc.2024.101089"},{"key":"409_CR72","unstructured":"Perry, B. I. et al. The psychosis metabolic risk calculator (PsyMetRiC) for young people with psychosis: international external validation and site-specific recalibration in two independent European samples. Lancet Reg. Health Eur. 22, 100493 (2022)."},{"key":"409_CR73","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.mito.2020.11.009","volume":"56","author":"RC Roberts","year":"2020","unstructured":"Roberts, R. C. Mitochondrial dysfunction in schizophrenia: with a focus on postmortem studies. Mitochondrion 56, 91 (2020).","journal-title":"Mitochondrion"},{"key":"409_CR74","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2353\/ajpath.2010.081068","volume":"177","author":"AM Cataldo","year":"2010","unstructured":"Cataldo, A. M. et al. Abnormalities in mitochondrial structure in cells from patients with bipolar disorder. Am. J. Pathol. 177, 575\u2013585 (2010).","journal-title":"Am. J. Pathol."},{"key":"409_CR75","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.2174\/092986711797379221","volume":"18","author":"D Marazziti","year":"2011","unstructured":"Marazziti, D. et al. Mitochondrial alterations and neuropsychiatric disorders. Curr. Med. Chem. 18, 4715\u20134721 (2011).","journal-title":"Curr. Med. Chem."},{"key":"409_CR76","doi-asserted-by":"crossref","unstructured":"Fiz\u00edkov\u00e1, I., Draga\u0161ek, J. & Ra\u010day, P. Mitochondrial dysfunction, altered mitochondrial oxygen, and energy metabolism associated with the pathogenesis of schizophrenia. Int. J. Mol. Sci. 24, 7991 (2023).","DOI":"10.3390\/ijms24097991"},{"key":"409_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000202822","volume":"59","author":"A Dietrich-Muszalska","year":"2009","unstructured":"Dietrich-Muszalska, A., Olas, B., G\u0142owacki, R. & Bald, E. Oxidative\/nitrative modifications of plasma proteins and thiols from patients with schizophrenia. Neuropsychobiology 59, 1\u20137 (2009).","journal-title":"Neuropsychobiology"},{"key":"409_CR78","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s11064-012-0707-3","volume":"37","author":"A Dietrich-Muszalska","year":"2012","unstructured":"Dietrich-Muszalska, A. et al. The oxidative stress may be induced by the elevated homocysteine in schizophrenic patients. Neurochem. Res. 37, 1057 (2012).","journal-title":"Neurochem. Res."},{"key":"409_CR79","doi-asserted-by":"publisher","unstructured":"Buck, S. A. et al. dVGLUT is a mediator of sex differences in dopamine neuron mitochondrial function across aging and in a Parkinson\u2019s disease model. Aging Cell https:\/\/doi.org\/10.1111\/ACEL.70096 (2025).","DOI":"10.1111\/ACEL.70096"},{"key":"409_CR80","doi-asserted-by":"publisher","first-page":"513996","DOI":"10.3389\/fpsyt.2020.00204","volume":"11","author":"NA Uranova","year":"2020","unstructured":"Uranova, N. A., Vikhreva, O. V., Rakhmanova, V. I. & Orlovskaya, D. D. Dystrophy of oligodendrocytes and adjacent microglia in prefrontal gray matter in schizophrenia. Front. Psychiatry 11, 513996 (2020).","journal-title":"Front. Psychiatry"},{"key":"409_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15622970902806124","volume":"11","author":"N Kolomeets","year":"2009","unstructured":"Kolomeets, N. & Uranova, N. Ultrastructural abnormalities of astrocytes in the hippocampus in schizophrenia and duration of illness: a postortem morphometric study. World J. Biol. Psychiatry 11, 1\u201311 (2009).","journal-title":"World J. Biol. Psychiatry"},{"key":"409_CR82","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/syn.20981","volume":"66","author":"SM Somerville","year":"2012","unstructured":"Somerville, S. M., Conley, R. R. & Roberts, R. C. Striatal mitochondria in subjects with chronic undifferentiated vs. chronic paranoid schizophrenia. Synapse 66, 29\u201341 (2012).","journal-title":"Synapse"},{"key":"409_CR83","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/BF01186670","volume":"22","author":"EA Aganova","year":"1992","unstructured":"Aganova, E. A. & Uranova, N. A. Morphometric analysis of synaptic contacts in the anterior limbic cortex in the endogenous psychoses. Neurosci. Behav. Physiol. 22, 59\u201365 (1992).","journal-title":"Neurosci. Behav. Physiol."},{"key":"409_CR84","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1017\/S1461145707007626","volume":"10","author":"NA Uranova","year":"2007","unstructured":"Uranova, N. A. et al. The role of oligodendrocyte pathology in schizophrenia. Int. J. Neuropsychopharmacol. 10, 537\u2013545 (2007).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"409_CR85","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.schres.2016.04.023","volume":"177","author":"OV Vikhreva","year":"2016","unstructured":"Vikhreva, O. V., Rakhmanova, V. I., Orlovskaya, D. D. & Uranova, N. A. Ultrastructural alterations of oligodendrocytes in prefrontal white matter in schizophrenia: a post-mortem morphometric study. Schizophr. Res. 177, 28\u201336 (2016).","journal-title":"Schizophr. Res."},{"key":"409_CR86","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0920-9964(96)00059-X","volume":"22","author":"NA Uranova","year":"1996","unstructured":"Uranova, N. A., Casanova, M. F., DeVaughn, N. M., Orlovskaya, D. D. & Denisov, D. V. Ultrastructural alterations of synaptic contacts and astrocytes in postmortem caudate nucleus of schizophrenic patients. Schizophr. Res. 22, 81\u201383 (1996).","journal-title":"Schizophr. Res."},{"key":"409_CR87","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.schres.2019.09.007","volume":"217","author":"ST Chan","year":"2019","unstructured":"Chan, S. T., McCarthy, M. J. & Vawter, M. P. Psychiatric drugs impact mitochondrial function in brain and other tissues. Schizophr. Res. 217, 136 (2019).","journal-title":"Schizophr. Res."},{"key":"409_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-24355-6","volume":"8","author":"T Da Silva","year":"2018","unstructured":"Da Silva, T. et al. Mitochondrial function in individuals at clinical high risk for psychosis. Sci. Rep. 8, 1\u201310 (2018).","journal-title":"Sci. Rep."},{"key":"409_CR89","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1177\/0706743716648290","volume":"61","author":"O Bergman","year":"2016","unstructured":"Bergman, O. & Ben-Shachar, D. Mitochondrial oxidative phosphorylation system (OXPHOS) deficits in schizophrenia: possible interactions with cellular processes. Can. J. Psychiatry 61, 457\u2013469 (2016).","journal-title":"Can. J. Psychiatry"},{"key":"409_CR90","first-page":"157","volume":"3","author":"BL Rollins","year":"2018","unstructured":"Rollins, B. L. et al. Mitochondrial complex I deficiency in schizophrenia and bipolar disorder and medication influence. Mol. Neuropsychiatry 3, 157\u2013169 (2018).","journal-title":"Mol. Neuropsychiatry"},{"key":"409_CR91","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/JCP.0b013e318054753e","volume":"27","author":"J Casademont","year":"2007","unstructured":"Casademont, J. et al. Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients. J. Clin. Psychopharmacol. 27, 284\u2013288 (2007).","journal-title":"J. Clin. Psychopharmacol."},{"key":"409_CR92","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0197-0186(00)00108-X","volume":"38","author":"S Balijepalli","year":"2001","unstructured":"Balijepalli, S., Kenchappa, R. S., Boyd, M. R. & Ravindranath, V. Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: comparison with atypical antipsychotics. Neurochem. Int. 38, 425\u2013435 (2001).","journal-title":"Neurochem. Int."},{"key":"409_CR93","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.euroneuro.2019.06.010","volume":"29","author":"L Holper","year":"2019","unstructured":"Holper, L., Ben-Shachar, D. & Mann, J. J. Psychotropic and neurological medication effects on mitochondrial complex I and IV in rodent models. Eur. Neuropsychopharmacol. 29, 986\u20131002 (2019).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"409_CR94","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jphs.2016.05.012","volume":"131","author":"Y Shinoda","year":"2016","unstructured":"Shinoda, Y. et al. Haloperidol aggravates transverse aortic constriction-induced heart failure via mitochondrial dysfunction. J. Pharmacol. Sci. 131, 172\u2013183 (2016).","journal-title":"J. Pharmacol. Sci."},{"key":"409_CR95","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3109\/00498254.2015.1078522","volume":"46","author":"A Eftekhari","year":"2016","unstructured":"Eftekhari, A., Azarmi, Y., Parvizpur, A. & Eghbal, M. A. Involvement of oxidative stress and mitochondrial\/lysosomal cross-talk in olanzapine cytotoxicity in freshly isolated rat hepatocytes. Xenobiotica 46, 363\u2013378 (2016).","journal-title":"Xenobiotica"},{"key":"409_CR96","doi-asserted-by":"publisher","first-page":"5","DOI":"10.15407\/ubj88.04.005","volume":"88","author":"LG Babich","year":"2016","unstructured":"Babich, L. G., Shlykov, S. G., Kushnarova, A. M. & Kosterin, S. O. Ca2+-dependent regulation of the Ca2+ concentration in the myometrium mitochondria. I. Trifluoperazine effects on mitochondria membranes polarization and [Ca2+]m. Ukr. Biochem. J. 88, 5\u201311 (2016).","journal-title":"Ukr. Biochem. J."},{"key":"409_CR97","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/pmic.201500242","volume":"16","author":"KO Schubert","year":"2016","unstructured":"Schubert, K. O., F\u00f6cking, M., Wynne, K. & Cotter, D. R. Proteome and pathway effects of chronic haloperidol treatment in mouse hippocampus. Proteomics 16, 532\u2013538 (2016).","journal-title":"Proteomics"},{"key":"409_CR98","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/pmic.201300466","volume":"14","author":"LA Farrelly","year":"2014","unstructured":"Farrelly, L. A. et al. Adolescent Risperidone treatment alters protein expression associated with protein trafficking and cellular metabolism in the adult rat prefrontal cortex. Proteomics 14, 1574\u20131578 (2014).","journal-title":"Proteomics"},{"key":"409_CR99","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.euroneuro.2018.01.004","volume":"28","author":"G Scaini","year":"2018","unstructured":"Scaini, G. et al. Second generation antipsychotic-induced mitochondrial alterations: Implications for increased risk of metabolic syndrome in patients with schizophrenia. Eur. Neuropsychopharmacol. 28, 369\u2013380 (2018).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"409_CR100","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1021\/pr800876z","volume":"8","author":"B Ji","year":"2009","unstructured":"Ji, B. et al. A comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications. J. Proteome Res. 8, 3633\u20133641 (2009).","journal-title":"J. Proteome Res."},{"key":"409_CR101","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-9-57","volume":"9","author":"KH Choi","year":"2009","unstructured":"Choi, K. H. et al. Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects. BMC Psychiatry 9, 57 (2009).","journal-title":"BMC Psychiatry"},{"key":"409_CR102","doi-asserted-by":"publisher","first-page":"e59012","DOI":"10.1371\/journal.pone.0059012","volume":"8","author":"V Contreras-Shannon","year":"2013","unstructured":"Contreras-Shannon, V. et al. Clozapine-induced mitochondria alterations and inflammation in brain and insulin-responsive cells. PLoS ONE 8, e59012 (2013).","journal-title":"PLoS ONE"},{"key":"409_CR103","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.bbi.2022.06.010","volume":"105","author":"A Bhat","year":"2022","unstructured":"Bhat, A. et al. Attenuated transcriptional response to pro-inflammatory cytokines in schizophrenia hiPSC-derived neural progenitor cells. Brain Behav. Immun. 105, 82\u201397 (2022).","journal-title":"Brain Behav. Immun."},{"key":"409_CR104","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1161\/CIRCRESAHA.124.323800","volume":"135","author":"A Hinton","year":"2024","unstructured":"Hinton, A. et al. Mitochondrial structure and function in human heart failure. Circ. Res. 135, 372\u2013396 (2024).","journal-title":"Circ. Res."},{"key":"409_CR105","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1371\/journal.pbio.0060301","volume":"6","author":"JP Copp\u00e9","year":"2008","unstructured":"Copp\u00e9, J. P. et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, e301 (2008).","journal-title":"PLoS Biol."},{"key":"409_CR106","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1083\/jcb.201009094","volume":"192","author":"F Rodier","year":"2011","unstructured":"Rodier, F. & Campisi, J. Four faces of cellular senescence. J. Cell Biol. 192, 547\u2013556 (2011).","journal-title":"J. Cell Biol."},{"key":"409_CR107","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/nrm.2016.157","volume":"17","author":"P Strzyz","year":"2016","unstructured":"Strzyz, P. Controlling the senescence-associated secretory phenotype. Nat. Rev. Mol. Cell Biol. 17, 740\u2013740 (2016).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"409_CR108","first-page":"1","volume":"8","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Immunosenescence: molecular mechanisms and diseases. Signal Transduct. Target. Ther. 8, 1\u201316 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"409_CR109","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1038\/s41380-024-02539-z","volume":"29","author":"S Chen","year":"2024","unstructured":"Chen, S., Tan, Y. & Tian, L. Immunophenotypes in psychosis: is it a premature inflamm-aging disorder? Mol. Psychiatry 29, 2834 (2024).","journal-title":"Mol. Psychiatry"},{"key":"409_CR110","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1749-6632.2000.tb06651.x","volume":"908","author":"C Franceschi","year":"2000","unstructured":"Franceschi, C. et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. N. Y. Acad. Sci. 908, 244\u2013254 (2000).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"409_CR111","doi-asserted-by":"publisher","first-page":"e13080","DOI":"10.1111\/acel.13080","volume":"19","author":"L Ferrucci","year":"2020","unstructured":"Ferrucci, L. et al. Measuring biological aging in humans: a quest. Aging Cell 19, e13080 (2020).","journal-title":"Aging Cell"},{"key":"409_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41413-021-00164-y","volume":"9","author":"M Wan","year":"2021","unstructured":"Wan, M., Gray-Gaillard, E. F. & Elisseeff, J. H. Cellular senescence in musculoskeletal homeostasis, diseases, and regeneration. Bone Res. 9, 1\u201312 (2021).","journal-title":"Bone Res."},{"key":"409_CR113","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/jbmr.2892","volume":"31","author":"JN Farr","year":"2016","unstructured":"Farr, J. N. et al. Identification of senescent cells in the bone microenvironment. J. Bone Miner. Res. 31, 1920\u20131929 (2016).","journal-title":"J. Bone Miner. Res."},{"key":"409_CR114","doi-asserted-by":"publisher","first-page":"e12771","DOI":"10.1111\/acel.12771","volume":"17","author":"BO Diekman","year":"2018","unstructured":"Diekman, B. O. et al. Expression of p16INK4a is a biomarker of chondrocyte aging but does not cause osteoarthritis. Aging Cell 17, e12771 (2018).","journal-title":"Aging Cell"},{"key":"409_CR115","doi-asserted-by":"crossref","unstructured":"Chen, Q. N. et al. Effect of sarcolipin-mediated cell transdifferentiation in sarcopenia-associated skeletal muscle fibrosis. Exp. Cell Res. 389, 111890 (2020).","DOI":"10.1016\/j.yexcr.2020.111890"},{"key":"409_CR116","doi-asserted-by":"publisher","first-page":"L162","DOI":"10.1152\/ajplung.00037.2018","volume":"315","author":"DW Waters","year":"2018","unstructured":"Waters, D. W. et al. Fibroblast senescence in the pathology of idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 315, L162\u2013L172 (2018).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"409_CR117","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.2337\/db14-1820","volume":"64","author":"AK Palmer","year":"2015","unstructured":"Palmer, A. K. et al. Cellular senescence in type 2 diabetes: a therapeutic opportunity. Diabetes 64, 2289\u20132298 (2015).","journal-title":"Diabetes"},{"key":"409_CR118","doi-asserted-by":"crossref","unstructured":"Bhat, R. et al. Astrocyte senescence as a component of Alzheimer\u2019s disease. PLoS ONE 7, e45069 (2012).","DOI":"10.1371\/journal.pone.0045069"},{"key":"409_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arr.2015.04.003","volume":"22","author":"V Boccardi","year":"2015","unstructured":"Boccardi, V., Pelini, L., Ercolani, S., Ruggiero, C. & Mecocci, P. From cellular senescence to Alzheimer\u2019s disease: the role of telomere shortening. Ageing Res. Rev. 22, 1\u20138 (2015).","journal-title":"Ageing Res. Rev."},{"key":"409_CR120","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1172\/JCI95145","volume":"128","author":"DJ Baker","year":"2018","unstructured":"Baker, D. J. & Petersen, R. C. Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. J. Clin. Investig. 128, 1208\u20131216 (2018).","journal-title":"J. Clin. Investig."},{"key":"409_CR121","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jagp.2016.08.018","volume":"25","author":"BS Diniz","year":"2017","unstructured":"Diniz, B. S. et al. Enhanced molecular aging in late-life depression: the senescent-associated secretory phenotype. Am. J. Geriatr. Psychiatry 25, 64\u201372 (2017).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"409_CR122","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jad.2024.05.071","volume":"360","author":"T Tessema","year":"2024","unstructured":"Tessema, T. et al. Elevated senescence-associated secretory phenotype index in late-life bipolar disorder. J. Affect. Disord. 360, 163\u2013168 (2024).","journal-title":"J. Affect. Disord."},{"key":"409_CR123","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.jagp.2019.06.006","volume":"27","author":"AP Mendes-Silva","year":"2019","unstructured":"Mendes-Silva, A. P. et al. Molecular senescence is associated with white matter microstructural damage in late-life depression. Am. J. Geriatr. Psychiatry 27, 1414\u20131418 (2019).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"409_CR124","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/7854_2018_88","volume":"44","author":"R Upthegrove","year":"2019","unstructured":"Upthegrove, R. & Khandaker, G. M. Cytokines, oxidative stress and cellular markers of inflammation in schizophrenia. Curr. Top. Behav. Neurosci. 44, 49\u201366 (2019).","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"409_CR125","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s11064-009-9922-y","volume":"34","author":"T Takeda","year":"2009","unstructured":"Takeda, T. Senescence-accelerated mouse (SAM) with special references to neurodegeneration models, SAMP8 and SAMP10 mice. Neurochem. Res. 34, 639\u2013659 (2009).","journal-title":"Neurochem. Res."},{"key":"409_CR126","doi-asserted-by":"crossref","unstructured":"Li, Q. et al. Clonal characteristics of T-cell receptor repertoires in violent and non-violent patients with schizophrenia. Front. Psychiatry 9, 403 (2018).","DOI":"10.3389\/fpsyt.2018.00403"},{"key":"409_CR127","doi-asserted-by":"publisher","first-page":"6926","DOI":"10.1038\/s41380-021-01308-6","volume":"26","author":"C Luo","year":"2021","unstructured":"Luo, C. et al. Subtypes of schizophrenia identified by multi-omic measures associated with dysregulated immune function. Mol. Psychiatry 26, 6926\u20136936 (2021).","journal-title":"Mol. Psychiatry"},{"key":"409_CR128","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41590-021-00927-z","volume":"22","author":"M Mittelbrunn","year":"2021","unstructured":"Mittelbrunn, M. & Kroemer, G. Hallmarks of T cell aging. Nat. Immunol. 22, 687\u2013698 (2021).","journal-title":"Nat. Immunol."},{"key":"409_CR129","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.cell.2020.06.026","volume":"182","author":"E Pasciuto","year":"2020","unstructured":"Pasciuto, E. et al. Microglia require CD4 T cells to complete the fetal-to-adult transition. Cell 182, 625\u2013640.e24 (2020).","journal-title":"Cell"},{"key":"409_CR130","doi-asserted-by":"crossref","unstructured":"Corsi-Zuelli, F. et al. T regulatory cells as a potential therapeutic target in psychosis? Current challenges and future perspectives. Brain Behav. Immun. Health 17, 100330 (2021).","DOI":"10.1016\/j.bbih.2021.100330"},{"key":"409_CR131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-33885-7","volume":"13","author":"ME Lynall","year":"2022","unstructured":"Lynall, M. E. et al. Genetic variants associated with psychiatric disorders are enriched at epigenetically active sites in lymphoid cells. Nat. Commun. 13, 1\u201315 (2022).","journal-title":"Nat. Commun."},{"key":"409_CR132","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.neubiorev.2021.03.004","volume":"125","author":"F Corsi-Zuelli","year":"2021","unstructured":"Corsi-Zuelli, F. & Deakin, B. Impaired regulatory T cell control of astroglial overdrive and microglial pruning in schizophrenia. Neurosci. Biobehav. Rev. 125, 637\u2013653 (2021).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"409_CR133","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2022.11.005","volume":"35","author":"SJ Han","year":"2023","unstructured":"Han, S. J., Georgiev, P., Ringel, A. E., Sharpe, A. H. & Haigis, M. C. Age-associated remodeling of T cell immunity and metabolism. Cell Metab. 35, 36\u201355 (2023).","journal-title":"Cell Metab."},{"key":"409_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-45742-w","volume":"15","author":"AG de la Fuente","year":"2024","unstructured":"de la Fuente, A. G. et al. Ageing impairs the regenerative capacity of regulatory T cells in mouse central nervous system remyelination. Nat. Commun. 15, 1\u201319 (2024).","journal-title":"Nat. Commun."},{"key":"409_CR135","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41590-022-01208-z","volume":"23","author":"L Yshii","year":"2022","unstructured":"Yshii, L. et al. Astrocyte-targeted gene delivery of interleukin 2 specifically increases brain-resident regulatory T cell numbers and protects against pathological neuroinflammation. Nat. Immunol. 23, 878\u2013891 (2022).","journal-title":"Nat. Immunol."},{"key":"409_CR136","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.bbi.2025.01.023","volume":"125","author":"F Corsi-Zuelli","year":"2025","unstructured":"Corsi-Zuelli, F. Chipping away at the iceberg: Uncovering immune complexity in schizophrenia. Brain Behav. Immun. 125, 410\u2013412 (2025).","journal-title":"Brain Behav. Immun."},{"key":"409_CR137","doi-asserted-by":"crossref","unstructured":"Li, W., Yong-Yan, X., Jia-Xin, M., Shu-Chao, G. & Li-Ping, H. Senescent microglia: the hidden culprits accelerating Alzheimer\u2019s disease. Brain Res. 1851, 149480 (2025).","DOI":"10.1016\/j.brainres.2025.149480"},{"key":"409_CR138","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/s41593-024-01620-8","volume":"27","author":"N Rachmian","year":"2024","unstructured":"Rachmian, N. et al. Identification of senescent, TREM2-expressing microglia in aging and Alzheimer\u2019s disease model mouse brain. Nat. Neurosci. 27, 1116\u20131124 (2024).","journal-title":"Nat. Neurosci."},{"key":"409_CR139","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41593-018-0334-7","volume":"22","author":"CM Sellgren","year":"2019","unstructured":"Sellgren, C. M. et al. Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nat. Neurosci. 22, 374 (2019).","journal-title":"Nat. Neurosci."},{"key":"409_CR140","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/bph.13364","volume":"173","author":"LE Laskaris","year":"2016","unstructured":"Laskaris, L. E. et al. Microglial activation and progressive brain changes in schizophrenia. Br. J. Pharmacol. 173, 666 (2016).","journal-title":"Br. J. Pharmacol."},{"key":"409_CR141","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.schres.2011.06.018","volume":"131","author":"G Juckel","year":"2011","unstructured":"Juckel, G. et al. Microglial activation in a neuroinflammational animal model of schizophrenia\u2014a pilot study. Schizophr. Res. 131, 96\u2013100 (2011).","journal-title":"Schizophr. Res."},{"key":"409_CR142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.62852","volume":"10","author":"M Yousefzadeh","year":"2021","unstructured":"Yousefzadeh, M. et al. DNA damage\u2014How and why we age? Elife 10, 1\u201317 (2021).","journal-title":"Elife"},{"key":"409_CR143","doi-asserted-by":"crossref","unstructured":"Chestkov, I. V. et al. ROS-Induced DNA damage associates with abundance of mitochondrial DNA in white blood cells of the untreated schizophrenic patients. Oxid. Med. Cell. Longev. 2018, 8587475 (2018).","DOI":"10.1155\/2018\/8587475"},{"key":"409_CR144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-31122-0","volume":"8","author":"P Kumar","year":"2018","unstructured":"Kumar, P. et al. Mitochondrial DNA copy number is associated with psychosis severity and anti-psychotic treatment. Sci. Rep. 8, 1\u201313 (2018).","journal-title":"Sci. Rep."},{"key":"409_CR145","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.schres.2024.08.011","volume":"272","author":"V Mlakar","year":"2024","unstructured":"Mlakar, V. et al. Telomere biology and its maintenance in schizophrenia spectrum disorders: exploring links to cognition. Schizophr. Res. 272, 89\u201395 (2024).","journal-title":"Schizophr. Res."},{"key":"409_CR146","doi-asserted-by":"crossref","unstructured":"Yu, W. Y., Chang, H. W., Lin, C. H. & Cho, C. L. Short telomeres in patients with chronic schizophrenia who show a poor response to treatment. J. Psychiatry Neurosci. 33, 244\u2013247 (2008).","DOI":"10.1139\/jpn.0825"},{"key":"409_CR147","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1017\/S0033291722002148","volume":"53","author":"C Gurvich","year":"2023","unstructured":"Gurvich, C. et al. The relationship between cognitive clusters and telomere length in bipolar-schizophrenia spectrum disorders. Psychol. Med. 53, 5119\u20135126 (2023).","journal-title":"Psychol. Med."},{"key":"409_CR148","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1038\/s41380-022-01541-7","volume":"27","author":"M Ayora","year":"2022","unstructured":"Ayora, M. et al. Leukocyte telomere length in patients with schizophrenia and related disorders: a meta-analysis of case-control studies. Mol. Psychiatry 27, 2968\u20132975 (2022).","journal-title":"Mol. Psychiatry"},{"key":"409_CR149","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s43587-021-00040-8","volume":"1","author":"S Saraswati","year":"2021","unstructured":"Saraswati, S., Mart\u00ednez, P., Gra\u00f1a-Castro, O. & Blasco, M. A. Short and dysfunctional telomeres sensitize the kidneys to develop fibrosis. Nat. Aging 1, 269\u2013283 (2021).","journal-title":"Nat. Aging"},{"key":"409_CR150","doi-asserted-by":"crossref","unstructured":"Povedano, J. M. et al. Therapeutic effects of telomerase in mice with pulmonary fibrosis induced by damage to the lungs and short telomeres. eLife 7, e31299 (2018).","DOI":"10.7554\/eLife.31299"},{"key":"409_CR151","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1038\/s41380-019-0601-3","volume":"25","author":"L Smigielski","year":"2020","unstructured":"Smigielski, L., Jagannath, V., R\u00f6ssler, W., Walitza, S. & Gr\u00fcnblatt, E. Epigenetic mechanisms in schizophrenia and other psychotic disorders: a systematic review of empirical human findings. Mol. Psychiatry 25, 1718\u20131748 (2020).","journal-title":"Mol. Psychiatry"},{"key":"409_CR152","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-024-01660-8","volume":"16","author":"APS Ori","year":"2024","unstructured":"Ori, A. P. S. et al. Meta-analysis of epigenetic aging in schizophrenia reveals multifaceted relationships with age, sex, illness duration, and polygenic risk. Clin. Epigenetics 16, 53 (2024).","journal-title":"Clin. Epigenetics"},{"key":"409_CR153","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.ajhg.2008.01.008","volume":"82","author":"J Mill","year":"2008","unstructured":"Mill, J. et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am. J. Hum. Genet. 82, 696\u2013711 (2008).","journal-title":"Am. J. Hum. Genet."},{"key":"409_CR154","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1038\/s41380-025-02909-1","volume":"30","author":"SA Buck","year":"2025","unstructured":"Buck, S. A. et al. Aging disrupts the coordination between mRNA and protein expression in mouse and human midbrain. Mol. Psychiatry 30, 3039\u20133054 (2025).","journal-title":"Mol. Psychiatry"},{"key":"409_CR155","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/jnr.20122","volume":"76","author":"S Dracheva","year":"2004","unstructured":"Dracheva, S., Elhakem, S. L., McGurk, S. R., Davis, K. L. & Haroutunian, V. GAD67 and GAD65 mRNA and protein expression in cerebrocortical regions of elderly patients with schizophrenia. J. Neurosci. Res. 76, 581\u2013592 (2004).","journal-title":"J. Neurosci. Res."},{"key":"409_CR156","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/mp.2013.152","volume":"19","author":"JR Glausier","year":"2014","unstructured":"Glausier, J. R., Fish, K. N. & Lewis, D. A. Altered parvalbumin basket cell inputs in the dorsolateral prefrontal cortex of schizophrenia subjects. Mol. Psychiatry 19, 30\u201336 (2014).","journal-title":"Mol. Psychiatry"},{"key":"409_CR157","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3390\/ijms23031539","volume":"23","author":"A Di Maio","year":"2022","unstructured":"Di Maio, A. et al. Analysis of mRNA and protein levels of CAP2, DLG1 and ADAM10 genes in post-mortem brain of schizophrenia, Parkinson\u2019s and Alzheimer\u2019s disease patients. Int. J. Mol. Sci. 23, 1539 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"409_CR158","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1038\/npp.2011.102","volume":"36","author":"JR Glausier","year":"2011","unstructured":"Glausier, J. R. & Lewis, D. A. Selective pyramidal cell reduction of GABAA receptor \u03b11 subunit messenger RNA expression in schizophrenia. Neuropsychopharmacology 36, 2103 (2011).","journal-title":"Neuropsychopharmacology"},{"key":"409_CR159","doi-asserted-by":"crossref","unstructured":"Chen, B. Y. et al. Neurodevelopment regulators miR-137 and miR-34 family as biomarkers for early and adult onset schizophrenia. npj Schizophr. 7, 35 (2021).","DOI":"10.1038\/s41537-021-00164-1"},{"key":"409_CR160","doi-asserted-by":"publisher","unstructured":"Upthegrove, R., Corsi-Zuelli, F., Couch, A. C. M., Barnes, N. M. & Vernon, A. C. Current position and future direction of inflammation in neuropsychiatric disorders: a review. JAMA Psychiatry https:\/\/doi.org\/10.1001\/JAMAPSYCHIATRY.2025.1369 (2025).","DOI":"10.1001\/JAMAPSYCHIATRY.2025.1369"},{"key":"409_CR161","doi-asserted-by":"publisher","first-page":"7117","DOI":"10.1073\/pnas.1719266115","volume":"115","author":"J Muffat","year":"2018","unstructured":"Muffat, J. et al. Human induced pluripotent stem cell-derived glial cells and neural progenitors display divergent responses to Zika and dengue infections. Proc. Natl. Acad. Sci. USA. 115, 7117\u20137122 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"409_CR162","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.stem.2021.04.004","volume":"28","author":"J Mertens","year":"2021","unstructured":"Mertens, J. et al. Age-dependent instability of mature neuronal fate in induced neurons from Alzheimer\u2019s patients. Cell Stem Cell 28, 1533\u20131548.e6 (2021).","journal-title":"Cell Stem Cell"},{"key":"409_CR163","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.stem.2022.11.010","volume":"29","author":"JR Herdy","year":"2022","unstructured":"Herdy, J. R. et al. Increased post-mitotic senescence in aged human neurons is a pathological feature of Alzheimer\u2019s disease. Cell Stem Cell 29, 1637\u20131652.e6 (2022).","journal-title":"Cell Stem Cell"},{"key":"409_CR164","doi-asserted-by":"publisher","unstructured":"Sellgren, C. M. et al. Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nat. Neurosci. https:\/\/doi.org\/10.1038\/s41593-018-0334-7 (2019).","DOI":"10.1038\/s41593-018-0334-7"},{"key":"409_CR165","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.schres.2018.10.023","volume":"206","author":"M Weiser","year":"2019","unstructured":"Weiser, M. et al. The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial. Schizophr. Res. 206, 325\u2013332 (2019).","journal-title":"Schizophr. Res."},{"key":"409_CR166","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S2215-0366(18)30345-6","volume":"5","author":"B Deakin","year":"2018","unstructured":"Deakin, B. et al. The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial. Lancet Psychiatry 5, 885 (2018).","journal-title":"Lancet Psychiatry"},{"key":"409_CR167","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663\u2013676 (2006).","journal-title":"Cell"},{"key":"409_CR168","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.bbi.2024.11.030","volume":"124","author":"A Szabo","year":"2025","unstructured":"Szabo, A. et al. NLRP3 inflammasome mediates astroglial dysregulation of innate and adaptive immune responses in schizophrenia. Brain Behav. Immun. 124, 144\u2013156 (2025).","journal-title":"Brain Behav. Immun."},{"key":"409_CR169","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/s41593-020-00724-1","volume":"23","author":"GH Park","year":"2020","unstructured":"Park, G. H. et al. Activated microglia cause metabolic disruptions in developmental cortical interneurons that persist in interneurons from individuals with schizophrenia. Nat. Neurosci. 23, 1352\u20131364 (2020).","journal-title":"Nat. Neurosci."},{"key":"409_CR170","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/s41587-023-02031-z","volume":"42","author":"E Hergenreder","year":"2024","unstructured":"Hergenreder, E. et al. Combined small-molecule treatment accelerates maturation of human pluripotent stem cell-derived neurons. Nat. Biotechnol. 42, 1515\u20131525 (2024).","journal-title":"Nat. Biotechnol."},{"key":"409_CR171","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-018-0366-5","volume":"9","author":"E Martinuzzi","year":"2019","unstructured":"Martinuzzi, E. et al. Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. Transl. Psychiatry 9, 1\u201313 (2019).","journal-title":"Transl. Psychiatry"},{"key":"409_CR172","doi-asserted-by":"publisher","first-page":"e067944","DOI":"10.1136\/bmjopen-2022-067944","volume":"13","author":"\u00c9M Foley","year":"2023","unstructured":"Foley, \u00c9M. et al. Protocol for the Psychosis Immune Mechanism Stratified Medicine (PIMS) trial: a randomised double-blind placebo-controlled trial of single-dose tocilizumab in patients with psychosis. BMJ Open 13, e067944 (2023).","journal-title":"BMJ Open"},{"key":"409_CR173","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/npp.2017.258","volume":"43","author":"RR Girgis","year":"2018","unstructured":"Girgis, R. R. et al. A randomized, double-blind, placebo-controlled clinical trial of tocilizumab, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia. Neuropsychopharmacology 43, 1317\u20131323 (2018).","journal-title":"Neuropsychopharmacology"},{"key":"409_CR174","doi-asserted-by":"publisher","first-page":"275","DOI":"10.4088\/JCP.15l09920","volume":"77","author":"BJ Miller","year":"2016","unstructured":"Miller, B. J., Dias, J. K., Lemos, H. P. & Buckley, P. F. An open-label, pilot trial of adjunctive tocilizumab in schizophrenia. J. Clin. Psychiatry 77, 275\u2013276 (2016).","journal-title":"J. Clin. Psychiatry"},{"key":"409_CR175","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bbi.2023.10.012","volume":"115","author":"TW Weickert","year":"2024","unstructured":"Weickert, T. W. et al. Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: a randomized control trial. Brain Behav. Immun. 115, 191\u2013200 (2024).","journal-title":"Brain Behav. Immun."},{"key":"409_CR176","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/YIC.0000000000000399","volume":"37","author":"M Motamed","year":"2022","unstructured":"Motamed, M. et al. Risperidone combination therapy with adalimumab for treatment of chronic schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. Int. Clin. Psychopharmacol. 37, 92\u2013101 (2022).","journal-title":"Int. Clin. Psychopharmacol."},{"key":"409_CR177","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jpsychires.2022.12.003","volume":"158","author":"S Bejerot","year":"2023","unstructured":"Bejerot, S. et al. Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder: two open-label pilot studies on treatment-resistant patients. J. Psychiatr. Res. 158, 319\u2013329 (2023).","journal-title":"J. Psychiatr. Res."},{"key":"409_CR178","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.schres.2023.02.020","volume":"254","author":"M Karbalaee","year":"2023","unstructured":"Karbalaee, M. et al. Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. Schizophr. Res. 254, 92\u201398 (2023).","journal-title":"Schizophr. Res."},{"key":"409_CR179","doi-asserted-by":"publisher","first-page":"12844","DOI":"10.18632\/aging.102557","volume":"11","author":"C von Kobbe","year":"2019","unstructured":"von Kobbe, C. Targeting senescent cells: approaches, opportunities, challenges. Aging 11, 12844\u201312861 (2019).","journal-title":"Aging"},{"key":"409_CR180","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41593-019-0372-9","volume":"22","author":"P Zhang","year":"2019","unstructured":"Zhang, P. et al. Senolytic therapy alleviates A\u03b2-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer\u2019s disease model. Nat. Neurosci. 22, 719\u2013728 (2019).","journal-title":"Nat. Neurosci."},{"key":"409_CR181","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","volume":"47","author":"LTJ Hickson","year":"2019","unstructured":"Hickson, L. T. J. et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine 47, 446\u2013456 (2019).","journal-title":"EBioMedicine"},{"key":"409_CR182","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.ebiom.2018.12.052","volume":"40","author":"JN Justice","year":"2019","unstructured":"Justice, J. N. et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine 40, 554\u2013563 (2019).","journal-title":"EBioMedicine"},{"key":"409_CR183","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.3390\/ijms25115904","volume":"25","author":"A Sfera","year":"2024","unstructured":"Sfera, A. et al. Novel insights into psychosis and antipsychotic interventions: from managing symptoms to improving outcomes. Int. J. Mol. Sci. 25, 5904 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"409_CR184","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1503\/jpn.100057","volume":"36","author":"O Dean","year":"2011","unstructured":"Dean, O., Giorlando, F. & Berk, M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J. Psychiatry Neurosci. 36, 78 (2011).","journal-title":"J. Psychiatry Neurosci."},{"key":"409_CR185","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","volume":"64","author":"M Berk","year":"2008","unstructured":"Berk, M. et al. N-acetyl cysteine as a glutathione precursor for schizophrenia\u2014a double-blind, randomized, placebo-controlled trial. Biol. Psychiatry 64, 361\u2013368 (2008).","journal-title":"Biol. Psychiatry"},{"key":"409_CR186","doi-asserted-by":"publisher","unstructured":"Qureshi, O. et al. Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation? Br. J. Pharmacol. https:\/\/doi.org\/10.1111\/BPH.70138 (2025).","DOI":"10.1111\/BPH.70138"},{"key":"409_CR187","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/jpet.108.143461","volume":"327","author":"B Yu","year":"2008","unstructured":"Yu, B. et al. Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency. J. Pharmacol. Exp. Ther. 327, 316\u2013323 (2008).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"409_CR188","doi-asserted-by":"crossref","unstructured":"Nau, F., Yu, B., Martin, D. & Nichols, C. D. Serotonin 5-HT2A receptor activation blocks TNF-\u03b1 mediated inflammation in vivo. PLoS ONE 8, e75426 (2013).","DOI":"10.1371\/journal.pone.0075426"},{"key":"409_CR189","doi-asserted-by":"crossref","unstructured":"Dakic, V. et al. Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT. Sci. Rep. 7, 12863 (2017).","DOI":"10.1038\/s41598-017-12779-5"},{"key":"409_CR190","doi-asserted-by":"publisher","first-page":"103033","DOI":"10.1016\/j.bcab.2024.103033","volume":"56","author":"T Zanikov","year":"2024","unstructured":"Zanikov, T. et al. Psilocybin and eugenol prevent DSS-induced neuroinflammation in mice. Biocatal. Agric. Biotechnol. 56, 103033 (2024).","journal-title":"Biocatal. Agric. Biotechnol."},{"key":"409_CR191","doi-asserted-by":"crossref","unstructured":"Yu, S. J. et al. Neuroprotective effects of psilocybin in a rat model of stroke. BMC Neurosci. 25, 49 (2024).","DOI":"10.1186\/s12868-024-00903-x"},{"key":"409_CR192","doi-asserted-by":"crossref","unstructured":"Kato, K. et al. Psilocybin treatment extends cellular lifespan and improves survival of aged mice. npj Aging 11, 55 (2025).","DOI":"10.1038\/s41514-025-00244-x"},{"key":"409_CR193","doi-asserted-by":"crossref","unstructured":"Tang, C., Chua, Y. C., Abdin, E., Subramaniam, M. & Verma, S. Twenty-four week, randomized, double-blind, placebo-controlled trial of metformin for antipsychotic-induced weight gain in patients with first-episode psychosis: a pilot study. Int. J. Environ. Res. Public Health 19, 137 (2022).","DOI":"10.3390\/ijerph19010137"},{"key":"409_CR194","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1176\/appi.ajp.2013.12010127","volume":"170","author":"LF Jarskog","year":"2013","unstructured":"Jarskog, L. F. et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am. J. Psychiatry 170, 1032\u20131040 (2013).","journal-title":"Am. J. Psychiatry"},{"key":"409_CR195","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/JCP.0000000000000392","volume":"35","author":"W Zheng","year":"2015","unstructured":"Zheng, W. et al. Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials. J. Clin. Psychopharmacol. 35, 499\u2013509 (2015).","journal-title":"J. Clin. Psychopharmacol."},{"key":"409_CR196","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41574-023-00833-4","volume":"19","author":"M Foretz","year":"2023","unstructured":"Foretz, M., Guigas, B. & Viollet, B. Metformin: update on mechanisms of action and repurposing potential. Nat. Rev. Endocrinol. 19, 1 (2023).","journal-title":"Nat. Rev. Endocrinol."},{"key":"409_CR197","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cmet.2020.04.001","volume":"32","author":"AS Kulkarni","year":"2020","unstructured":"Kulkarni, A. S., Gubbi, S. & Barzilai, N. Benefits of metformin in attenuating the hallmarks of aging. Cell Metab. 32, 15\u201330 (2020).","journal-title":"Cell Metab."},{"key":"409_CR198","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.bbi.2024.09.005","volume":"123","author":"M Leboyer","year":"2025","unstructured":"Leboyer, M. et al. Low-dose interleukin-2 in patients with bipolar depression: a phase 2 randomised double-blind placebo-controlled trial. Brain Behav. Immun. 123, 177\u2013184 (2025).","journal-title":"Brain Behav. Immun."},{"key":"409_CR199","first-page":"1","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng, Z. et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct. Target. Ther. 9, 1\u201329 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"409_CR200","doi-asserted-by":"crossref","unstructured":"Que, Q. et al. The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA\/CREB pathway in a rat model of knee osteoarthritis. J. Inflamm. 16, 13 (2019).","DOI":"10.1186\/s12950-019-0218-y"},{"key":"409_CR201","doi-asserted-by":"crossref","unstructured":"Mehdi, S. F. et al. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front. Immunol. 14, 1148209 (2023).","DOI":"10.3389\/fimmu.2023.1148209"},{"key":"409_CR202","doi-asserted-by":"crossref","unstructured":"Cordeanu, E. M. et al. GLP1 receptor agonists exhibit antioxidant and anti-inflammatory properties in human heart tissue via the canonical GLP1 receptor expression through a AMPK-mediated pathway. Eur. Heart J. 44(Supplement_2), ehad655-2825 (2023).","DOI":"10.1093\/eurheartj\/ehad655.2825"},{"key":"409_CR203","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen, S. L. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diab. Endocrinol. 7, 776\u2013785 (2019).","journal-title":"Lancet Diab. Endocrinol."},{"key":"409_CR204","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.neuropharm.2014.07.015","volume":"86","author":"PL McClean","year":"2014","unstructured":"McClean, P. L. & H\u00f6lscher, C. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer\u2019s disease. Neuropharmacology 86, 241\u2013258 (2014).","journal-title":"Neuropharmacology"},{"key":"409_CR205","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/jnr.21483","volume":"86","author":"G Bertilsson","year":"2008","unstructured":"Bertilsson, G. et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson\u2019s disease. J. Neurosci. Res. 86, 326\u2013338 (2008).","journal-title":"J. Neurosci. Res."},{"key":"409_CR206","first-page":"951","volume":"31","author":"Y Xie","year":"2025","unstructured":"Xie, Y., Choi, T. & Al-Aly, Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat. Med. 2025 31, 951\u2013962 (2025). 31:3.","journal-title":"Nat. Med. 2025"},{"key":"409_CR207","doi-asserted-by":"publisher","first-page":"346432","DOI":"10.3389\/fendo.2018.00258","volume":"9","author":"A Rebelo-Marques","year":"2018","unstructured":"Rebelo-Marques, A. et al. Aging hallmarks: The benefits of physical exercise. Front. Endocrinol. 9, 346432 (2018).","journal-title":"Front. Endocrinol."},{"key":"409_CR208","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.bbi.2024.06.017","volume":"120","author":"C Dunleavy","year":"2024","unstructured":"Dunleavy, C. et al. Exercise4Psychosis: a randomised control trial assessing the effect of moderate-to-vigorous exercise on inflammatory biomarkers and negative symptom profiles in men with first-episode psychosis. Brain Behav. Immun. 120, 379\u2013390 (2024).","journal-title":"Brain Behav. Immun."},{"key":"409_CR209","doi-asserted-by":"publisher","first-page":"afaf067","DOI":"10.1093\/ageing\/afaf067","volume":"54","author":"M Bloomberg","year":"2025","unstructured":"Bloomberg, M. & Steptoe, A. Sex and education differences in trajectories of physiological ageing: longitudinal analysis of a prospective English cohort study. Age Ageing 54, afaf067 (2025).","journal-title":"Age Ageing"},{"key":"409_CR210","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1038\/s41562-021-01135-3","volume":"5","author":"MC Mills","year":"2021","unstructured":"Mills, M. C. et al. Identification of 371 genetic variants for age at first sex and birth linked to externalising behaviour. Nat. Hum. Behav. 5, 1717\u20131730 (2021).","journal-title":"Nat. Hum. Behav."},{"key":"409_CR211","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.schres.2024.07.046","volume":"271","author":"A Salvad\u00e9","year":"2024","unstructured":"Salvad\u00e9, A. et al. Gender differences in first episode psychosis: some arguments to develop gender specific treatment strategies. Schizophr. Res. 271, 300\u2013308 (2024).","journal-title":"Schizophr. Res."},{"key":"409_CR212","doi-asserted-by":"publisher","first-page":"872867","DOI":"10.3389\/fnagi.2022.872867","volume":"14","author":"C Demro","year":"2022","unstructured":"Demro, C. et al. Advanced brain-age in psychotic psychopathology: evidence for transdiagnostic neurodevelopmental origins. Front. Aging Neurosci. 14, 872867 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"409_CR213","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-16639-9","volume":"12","author":"Z Raisi-Estabragh","year":"2022","unstructured":"Raisi-Estabragh, Z. et al. Estimation of biological heart age using cardiovascular magnetic resonance radiomics. Sci. Rep. 12, 1\u201312 (2022).","journal-title":"Sci. Rep."},{"key":"409_CR214","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.jacc.2021.12.017","volume":"79","author":"L Liberale","year":"2022","unstructured":"Liberale, L. et al. Inflammation, aging, and cardiovascular disease: JACC Review Topic of the Week. J. Am. Coll. Cardiol. 79, 837\u2013847 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"409_CR215","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nature15526","volume":"527","author":"J Mertens","year":"2015","unstructured":"Mertens, J. et al. Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. Nature 527, 95\u201399 (2015).","journal-title":"Nature"}],"container-title":["npj Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41514-026-00409-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41514-026-00409-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41514-026-00409-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:03:57Z","timestamp":1787742237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41514-026-00409-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":215,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["409"],"URL":"https:\/\/doi.org\/10.1038\/s41514-026-00409-2","relation":{},"ISSN":["2731-6068"],"issn-type":[{"value":"2731-6068","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.U. reports consultancy for Bristol Meyers Squibb and speaker fee for educational events from Otuska and Viatris outside of the current work. T.P. has received speaker or consultancy fees from Boehringer Ingelheim, Bristol Myers Squibb, CNX Therapeutics, Janssen, Lecturing Minds Stockholm AB, Lundbeck, Otsuka, Recordati, ROVI Biotech, Schwabe Pharma, Sunovion, and Teva Pharmaceuticals; he receives book royalties from Wiley Blackwell; and he co-directs a company that designs digital resources to support treatment of mental illness. B.I.P. is founder of the PsyMetRiC Operating Division in partnership with University of Birmingham Enterprise, but does not receive any direct personal financial benefit. B.I.P. is Topic Advisor for Severe and Enduring Mental Illness for the National Institute for Health and Care Excellence (NICE). B.I.P. is a member of the Digital Mental Health A.I. Airlock Governance Board for the Medicines and Healthcare products Regulatory Agency (MHRA). P.A.L. has received honoraria for talks presented at educational meetings organized by Boehringer Ingelheim outside of the submitted work reports being a Director and shareholder of Celentyx Ltd although these associations are outside the current work.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"120"}}